Skip to main content
. 2019 Nov 21;19(1):762–770. doi: 10.3892/etm.2019.8225

Figure 2.

Figure 2.

Lenvatinib inhibited tumor growth of NSCLC and downregulated VEGFR and FGFR. (A) Treatment with 20, 40 and 100 mg/ml lenvatinib (A) significantly inhibited the growth of H1975 and H358 cells and (B) significantly induced the apoptosis of H1975 and H358 cells following 48-h treatment compared with control cells. (C) Treatment with 40 mg/ml lenvatinib downregulated VEGFR1-3 expression in H1975 cells compared with untreated controls. (D) Treatment with 40 mg/ml lenvatinib downregulated FGFR1-4 expression in H1975 cells compared untreated control. (E) Treatment with 40 mg/ml lenvatinib downregulated protein expression of VEGFR1-3 and FGFR1-4 in H1975 cells compared with untreated controls. **P<0.01 vs. control; ##P<0.01 vs. lenvatinib 20 mg/ml. Data are presented as mean ± standard error of the mean. NSCLC, non-small cell lung cancer; VEGFR, vascular endothelial growth factor receptor; FGFR, fibroblast growth factor receptor.